181 related articles for article (PubMed ID: 16449344)
1. Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty.
Badaru A; Wilson DM; Bachrach LK; Fechner P; Gandrud LM; Durham E; Wintergerst K; Chi C; Klein KO; Neely EK
J Clin Endocrinol Metab; 2006 May; 91(5):1862-7. PubMed ID: 16449344
[TBL] [Abstract][Full Text] [Related]
2. A randomized trial of 1- and 3-month depot leuprolide doses in the treatment of central precocious puberty.
Fuld K; Chi C; Neely EK
J Pediatr; 2011 Dec; 159(6):982-7.e1. PubMed ID: 21798557
[TBL] [Abstract][Full Text] [Related]
3. Two-year results of treatment with depot leuprolide acetate for central precocious puberty.
Neely EK; Hintz RL; Parker B; Bachrach LK; Cohen P; Olney R; Wilson DM
J Pediatr; 1992 Oct; 121(4):634-40. PubMed ID: 1403402
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty.
Lee PA; Klein K; Mauras N; Neely EK; Bloch CA; Larsen L; Mattia-Goldberg C; Chwalisz K
J Clin Endocrinol Metab; 2012 May; 97(5):1572-80. PubMed ID: 22344198
[TBL] [Abstract][Full Text] [Related]
5. Comparison of three doses of leuprolide acetate in the treatment of central precocious puberty: preliminary results.
Mericq V; Lammoglia JJ; Unanue N; Villaroel C; Hernández MI; Avila A; Iñiguez G; Klein KO
Clin Endocrinol (Oxf); 2009 Nov; 71(5):686-90. PubMed ID: 19302581
[TBL] [Abstract][Full Text] [Related]
6. A single luteinizing hormone determination 2 hours after depot leuprolide is useful for therapy monitoring of gonadotropin-dependent precocious puberty in girls.
Brito VN; Latronico AC; Arnhold IJ; Mendonca BB
J Clin Endocrinol Metab; 2004 Sep; 89(9):4338-42. PubMed ID: 15356030
[TBL] [Abstract][Full Text] [Related]
7. The relationship between luteinizing hormone and estradiol secretion in female precocious puberty: evaluation by sensitive gonadotropin assays and the leuprolide stimulation test.
Garibaldi LR; Aceto T; Weber C; Pang S
J Clin Endocrinol Metab; 1993 Apr; 76(4):851-6. PubMed ID: 8473395
[TBL] [Abstract][Full Text] [Related]
8. Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg).
Carel JC; Lahlou N; Jaramillo O; Montauban V; Teinturier C; Colle M; Lucas C; Chaussain JL
J Clin Endocrinol Metab; 2002 Sep; 87(9):4111-6. PubMed ID: 12213857
[TBL] [Abstract][Full Text] [Related]
9. 36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty.
Lee PA; Klein K; Mauras N; Lev-Vaisler T; Bacher P
J Clin Endocrinol Metab; 2014 Sep; 99(9):3153-9. PubMed ID: 24926950
[TBL] [Abstract][Full Text] [Related]
10. Serum luteinizing hormone rises within minutes after depot leuprolide injection: implications for monitoring therapy.
Bhatia S; Neely EK; Wilson DM
Pediatrics; 2002 Feb; 109(2):E30. PubMed ID: 11826240
[TBL] [Abstract][Full Text] [Related]
11. Suppression of gonadotropin secretion by a long-acting gonadotropin-releasing hormone analog (leuprolide acetate, Lupron Depot) in children with precocious puberty.
Kappy M; Stuart T; Perelman A; Clemons R
J Clin Endocrinol Metab; 1989 Nov; 69(5):1087-9. PubMed ID: 2507570
[TBL] [Abstract][Full Text] [Related]
12. Monitoring treatment of central precocious puberty using basal luteinizing hormone levels and practical considerations for dosing with a 3-month leuprolide acetate formulation.
Lee PA; Luce M; Bacher P
J Pediatr Endocrinol Metab; 2016 Nov; 29(11):1249-1257. PubMed ID: 27740929
[TBL] [Abstract][Full Text] [Related]
13. Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty.
Carel JC; Blumberg J; Seymour C; Adamsbaum C; Lahlou N;
Eur J Endocrinol; 2006 Jan; 154(1):119-24. PubMed ID: 16382000
[TBL] [Abstract][Full Text] [Related]
14. Luteinizing hormone (LH) and estradiol suppression and growth in girls with central precocious puberty: is more suppression better? Are pre-injection LH levels useful in monitoring treatment?
Kunz GJ; Sherman TI; Klein KO
J Pediatr Endocrinol Metab; 2007 Nov; 20(11):1189-98. PubMed ID: 18183790
[TBL] [Abstract][Full Text] [Related]
15. Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty.
Clemons RD; Kappy MS; Stuart TE; Perelman AH; Hoekstra FT
Am J Dis Child; 1993 Jun; 147(6):653-7. PubMed ID: 8506834
[TBL] [Abstract][Full Text] [Related]
16. Changes in body mass index during gonadotropin-releasing hormone agonist treatment for central precocious puberty and early puberty.
Lee HS; Yoon JS; Roh JK; Hwang JS
Endocrine; 2016 Nov; 54(2):497-503. PubMed ID: 27444748
[TBL] [Abstract][Full Text] [Related]
17. Spontaneous serum gonadotropin concentrations in the evaluation of precocious puberty.
Neely EK; Wilson DM; Lee PA; Stene M; Hintz RL
J Pediatr; 1995 Jul; 127(1):47-52. PubMed ID: 7608810
[TBL] [Abstract][Full Text] [Related]
18. Assessment of gonadotrophin suppression in girls treated with GnRH analogue for central precocious puberty; validity of single luteinizing hormone measurement after leuprolide acetate injection.
Demirbilek H; Alikasifoglu A; Gonc NE; Ozon A; Kandemir N
Clin Endocrinol (Oxf); 2012 Jan; 76(1):126-30. PubMed ID: 21790701
[TBL] [Abstract][Full Text] [Related]
19. Depot leuprolide acetate for treatment of precocious puberty.
Parker KL; Lee PA
J Clin Endocrinol Metab; 1989 Sep; 69(3):689-91. PubMed ID: 2503536
[TBL] [Abstract][Full Text] [Related]
20. Assessment of depot leuprolide acetate dose-adequacy for central precocious puberty.
Cook JS; Doty KL; Conn PM; Hansen JR
J Clin Endocrinol Metab; 1992 May; 74(5):1206-9. PubMed ID: 1569169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
